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University of Duisburg-Essen, University Hospital Essen, Essen, GermanyIntroduction: Because of the shortage of available organs for renal transplantation, strategies enabling the
safe use of organs from donors with potential chronic infections such as hepatitis C are necessary. The aim
of this study was to analyze the outcome of renal transplant donation from hepatitis C virus (HCV)-positive
donors.
Methods: Between September 2002 and May 2007, 51 kidneys (34 donors) reactive for HCV antibodies
were further evaluated. Six kidneys (5 donors) were transplanted to 6 recipients with known chronic HCV
infection. The remaining 29 donors underwent extended virological testing. Nine donors were HCV RNA
positive and thus not suitable for HCV-negative patients. Twenty donors (21 kidneys) did not have
detectable HCV RNA copies and were transplanted into 21 HCV-negative recipients. Clinical outcomes
focusing on safety, allograft function, and de novo HCV infection in the recipient were collected.
Results: There were no de novo HCV infections detected in recipients who were HCV negative before
transplantation. The extended virological donor screening did not have an impact on median cold
ischemia time. Five-year graft survival was 75%.
Discussion: Organs from anti-HCV-reactive, nonviremic donors can be transplanted safely to HCV-
negative recipients.
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1 demonstrated that hepatitis C
virus (HCV) can be transmitted by organ trans-
plantation. The number of organ donors showing an-
tibodies against HCV (HCV-AB) is estimated to be
approximately 5% of all potential cadaveric organ
donors in Europe and the USA.2–4 In contrast, the
prevalence of HCV is estimated be around 0.5% to
0.7% in the German adult general population (HCV-AB
positive).5–7 For other countries in Western Europe, the
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International Reports (2017) 2, 53–59into account the shortage of organs, loss of organ do-
nors due to false-positive HCV-AB is a relevant prob-
lem in transplantation.
Transplanting HCV-positive recipients entails a
number of clinical consequences such as limited HCV
treatment options after transplantation, limited graft
and/or patient survival, and exacerbation of liver dis-
ease. Nevertheless, kidney transplantation is currently
the preferred treatment option for patients with end-
stage renal disease and HCV infection who do not
present with liver cirrhosis.9–14
Because of ongoing controversy surrounding the
consequences of transplanting HCV-positive kidney
recipients with HCV-positive organs, most trans-
plantation centers in the Eurotransplant region are not
willing to transplant kidneys of HCV-positive donors.
The transplantation of HCV-AB-positive organs to53
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transplantation centers at present. In the past, different
policies regarding the use of these organs were estab-
lished.1,15–18
Because of the shortage of organs, strategies for the use
of organs from HCV-AB-positive donors need to be
developed. New and rapid virological test methods for
HCV are enabling strategies that had been impossible in
the past considering the time frame of organ procure-
ment and transplantation. Different methodologies are
usually applied to assess the HCV status of a donor.
Enzyme immunoassays (EIAs) serve as screening tests to
assess the presence of anti-HCV antibodies. The speci-
ﬁcity of the test result and the presence of anti-HCV
antibodies can be conﬁrmed by western blot-based
methods. However, the infectivity of a donor cannot
be judged entirely on the grounds of antibody serology.
The viral load of the donor is crucial to determine the risk
of infection and can be assessed by nucleic acid testing
(NAT). Thus, the evaluation of HCV-positive donors is
complex and multiple test methodologies are needed to
assess the infectivity of a donor.
The aim of this study was to analyze the clinical
outcome of HCV-negative recipients who were trans-
planted with renal allografts from nonviremic HCV-AB-
reactive donors. Thus, clinical outcome focusing on de
novo HCV infections, cold ischemia time, allograft
function, and safety was assessed.
METHODS
Organ Donors
Between September 2002 and May 2007, 269 kidneys
from deceased organ donors were accepted for adult
recipients at our transplant center. A total of 51 kid-
neys from 34 donors were tested positive or borderline
positive for HCV-AB in the organ donor screening
(ODS). All organs were stored by standard cold storage.
Six kidneys of 5 donors with a positive HCV-AB test
were transplanted to 6 recipients with known chronic
HCV infection before extended virological testing. The
remaining 29 of 34 donors (donating 45 kidneys) tested
positive or borderline for HCV-AB in the initial
screening were subject to the extended donor screening.
Extended Donor Screening
The extended donor screening included qualitative
or quantitative HCV RNA testing. All testing proced-
ures available at the time of the organs’ arrival
at our hospital were used for analysis. This included
the repetition of an EIA (third generation Bio-
Rad, Munich, Germany), replaced by enhanced chem-
iluminescence microparticle immunoassay (CMIA,
Abbott, Wiesbaden, Germany) since August 2004
for HCV-AB. The speciﬁcity of reactive results in the54HCV-AB immunoassay was further conﬁrmed by an
immunoblot (Blot, Mikrogen, Neuried, Germany), po-
lymerase chain reaction (Roche, Basel, Suisse; lower
limit of detection 50 IU/ml), or transcription-mediated
ampliﬁcation (Siemens, Munich, Germany; lower limit
of detection 10 IU/ml). Whenever possible, all 3 testing
procedures were performed simultaneously. According
to the results of the enhanced donor screening, the
renal allografts were handled as follows:
 Organs from donors that tested reactive in the ODS
without any additional testing were declared HCV
positive and were only transplanted to recipients
with chronic HCV infection.
 Organs from donors that were tested reactive for HCV
in the ODS and were conﬁrmed to be positive for HCV
RNA in the extended donor screening were only
transplanted to recipients with chronic HCV infection.
 Organs from donors that were tested reactive for HCV
in the ODS and were negative for HCV RNA in the
extended donor screening were transplanted either to
recipients with chronic HCV infection or to recipients
who were negative for HCV.
Transplant Recipients
Recipients were predeﬁned by the Eurotransplant
allocation protocol. If kidneys are rejected by 5
different centers, a different allocation algorithm is
applied according to the Eurotransplant protocol. In
this case, the organs are allocated according to the rules
for extended allocation and rescue allocation. These
rules are explicitly explained and deﬁned in chapter 3
of the Eurotransplant manual.19 Recipients for “Organ
rescue allocations” were chosen via interdisciplinary
consent with the best medical judgment regarding the
risk-beneﬁt proﬁle. In total, 21 patients negative for
HCV (HCV group) received renal allografts from donors
being reactive for HCV-AB in the ODS but were lacking
detectable HCV RNA. The recipients were explicitly
informed about the risk to acquire an HCV infection
that is estimated to be low. Every recipient gave
written informed consent concerning this risk.
Deﬁnitions and Statistic Analysis
The waiting time was calculated as the time from ﬁrst
dialysis to transplantation. Also, the time on the trans-
plant listwas calculated as the time frombeing registered
by Eurotransplant until the day of transplantation.
These results were compared with the waiting
time and time on transplant list of 253 other adult renal
recipients who underwent solitary cadaver kidney
transplantation at our center during the same period.
Data concerning graft function (creatinine, urea),
liver function (alanine aminotransferase, aspartate
aminotransferase, gamma-glutamyl transferase,Kidney International Reports (2017) 2, 53–59
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tests for HCV by CMIA or polymerase chain reaction/
transcription-mediated ampliﬁcation were collected and
analyzed retrospectively.
The deceased donor score was calculated for the
evaluation of the donor according to Nyberg et al.20
For the evaluation of quantitative variables, the
Mann-Whitney U test was used. These data are pre-
sented as medians with range. Qualitative variables
were compared with the c2 and/or Fisher exact test. A
P value < 0.05 was considered to be signiﬁcant.
RESULTS
Extended Donor Screening Findings
Six kidneys of 5 donors with a positive HCV-AB test in
the ODS were transplanted to 6 recipients with known
chronic HCV infection before extended virological
testing. The specimens of the remaining 29 HCV-AB-
reactive organ donors underwent extended virological
testing for HCV including EIA or CMIA, immunoblot
and/or NAT. The test results are given in detail inFigure 1. Test results of the extended donor screening. CMIA, chemilum
HCV, hepatitis C virus; PCR, polymerase chain reaction; TMA, transcriptio
Kidney International Reports (2017) 2, 53–59Figure 1. Brieﬂy, 28 of 29 organ donors were further
evaluated with NAT for detectable HCV RNA. Eight
donors were positive for HCV RNA. Interestingly, all of
these 8 donors were shown to have a positive immu-
noblot. These viremic donors were considered as
potentially infective and in general unsuitable for
HCV-negative recipients. The remaining 20 donors
(71%) lacked detectable HCV RNA. Thus, these donors
were considered suitable for HCV-negative recipients
and 21 allografts were transplanted accordingly. In all
cases, in which EIA/CMIA showed no reactivity on
repetition, HCV RNA was not detectable by NAT
(detailed results are shown in Table 1). Speciﬁcity,
sensitivity, negative and positive predictive values of
the immunoblot, and the EIA/CMIA in comparison
with NAT are outlined in Table 2.
Analysis of Demographic Data
The study population of HCV-negative recipients showed
no signiﬁcant differences in waiting time. Interestingly,
the mean cold ischemia time was not signiﬁcantlyinescence microparticle immunoassay; EIA, enzyme immunoassay;
n-mediated ampliﬁcation.
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Table 2. Validation of tests compared with nucleic acid testing
Immunoblot EIA/CMIA
Positive predictive value 87.5% (7/8)a
70% (7/10)b
70% (7/10)
Negative predictive value 100% (8/8) 100% (9/9)
Sensitivity 100% (7/7) 100% (7/7)
Speciﬁcity 88.8% (8/9)a
72.4 (8/11)b
75% (9/12)
CMIA, chemiluminescence microparticle immunoassay; EIA, enzyme immunoassay.
aIf doubtful is interpreted as negative.
bIf doubtful is interpreted as reactive.
Table 1. Results of the extended organ donor screening
Donor no. Immunoblot EIA/CMIA PCR/TMA b-DNA (IU/ml) Genotype Location of test
1 Not tested
2 Not tested
3 Negative Negative Negative Donor region
4 Not tested
5 Negative Negative Recipient center
6 Negative Recipient center
7 Negative Recipient center
8 Positive Positive Positive 490,000 2b Recipient center
9 Positive Positive Positive 27,000 1b Recipient center
10 Positive Donor region
11 Negative Positive Negative Recipient center
12 Not tested
13 Not tested
14 Negative Negative Negative Recipient center
15 Positive Positive Positive 297,700 1b Recipient center
16 Positive Positive Positive 587,700 1b Recipient center
17 Negative Positive Negative Recipient center
18 Negative Negative Negative Recipient center
19 Negative Negative Negative Recipient center
20 Negative Negative Recipient center
21 Negative Negative Recipient center
22 Negative Donor region
23 Positive Positive Positive 2,265,000 Recipient center
24 Doubtful Negative Recipient center
25 Doubtful Negative Donor region
26 Positive Positive Positive <615 n.a. Recipient center
27 Positive Positive Positive 10,600 n.a. Recipient center
28 Negative Negative Recipient center
29 Negative Negative Recipient center
30 Positive 3,780,000 1a Donor region
31 Positive Positive Negative Recipient center
32 Negative Negative Negative Donor region
33 Negative Donor region
34 Negative Donor region
CMIA, chemiluminescence microparticle immunoassay; EIA, enzyme immunoassay; PCR, polymerase chain reaction; TMA, transcription-mediated ampliﬁcation.
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testing including NAT. The donor age was signiﬁcantly
younger compared with the controls (Table 3).
Deceased Donor Score Findings and Transplant
Outcome
The analysis of the deceased donor score shows that
17 of 21 kidneys (81%) were classiﬁed as category A
or B. There were 2 graft losses in the ﬁrst year after
transplantation. Of 19 recipients, 16 (84%) had a
serum creatinine below 2 mg/dl after 1 year (Table 4).
Five-year allograft survival was 75%. No patient
developed HCV as shown by repeated negative
HCV-AB tests during an observation period of at least
43 months after transplantation. There was a mini-
mum time lag of 18 months between transplantation
and the tests performed. In all but 4 patients, results
from post-transplant HCV NAT were available. None
of the patients tested had detectable HCV RNA viral
load.56DISCUSSION
Our study demonstrates that renal allografts of HCV-
AB-reactive, nonviremic donors can be used safely
for HCV-negative recipients. Furthermore, we showed
that cold ischemia time is not signiﬁcantly inﬂuenced
by extended virological testing. Moreover, renal allo-
graft survival was excellent with 75% at 5 years.
De novo infection of recipients with HCV is a rele-
vant issue in organ transplantation. Reports ofKidney International Reports (2017) 2, 53–59
Table 3. Analysis of demographic data
Subject Controls HCV-negative recipients P value
Patients n ¼ 253 n ¼ 21
Time on waiting list (mo) 72. (2.24–182.12) 65 (19.79–101.87) 0.45
Time on transplant list (mo) 45 (0.49–128.50) 44 (4.17–97.3) 0.57
Cold ischemic time 16 h 31 min (4 h 25 min–32 h) 18 h 58 min (10 h 30 min–24 h 44 min) 0.06
Donor age 53 (15–86) 41.5 (14–71) <0.001
HCV, hepatitis C virus.
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raised a debate about high-risk donors and NAT.21–23
The estimated number of organ donors being reactive
for HCV-AB is different from ﬁndings of other cross-
sectional studies;2–8 this discrepancy can be explained
by the increased sensitivity and speciﬁcity of the
serological tests for HCV available. Reactivity for HCV-
AB needs further interpretation and conﬁrmation; it
can imply acute seroconversion in HCV infection,
chronic infection, persisting reactivity after eliminated
HCV infection, or a false-positive test.24 Thus, different
strategies exist to identify donors with very low risk of
infectivity. The results of the extended donor
screening in this analysis underline the complexity to
characterize the infectivity of a donor at the time of
organ donation. It is useful to repeat the serological
testing for detection of HCV antibodies and to conﬁrm
the previous result with immunoblot. In our study, 9 of
20 donors failed to show HCV-AB in the repeated EIA/
CMIA, whereas 11 were repeatedly positive. Of these
11 cases, 10 were assayed again in an immunoblot and
the presence of HCV antibodies was conﬁrmed in 8
cases. However, serological assays indicate recent or
past HCV infection but do not reﬂect current infec-
tivity. Viremia indicates infectivity of the donor, and
transplantation of these organs leads to de novo HCV
infection or superinfection in the case of genotype
mismatch in a recipient.25–28 Therefore, it is necessary
to perform NAT in every case in which a reactiveTable 4. Deceased donor score ﬁndings and renal allograft
outcome
HCV-negative recipients
Graft loss 2
Patient loss 0
DDS category
A 6
B 11
C 3
D 1
Creatinine (1 yr)
<1.5 mg/dl 11
>1.5–<2 mg/dl 5
>2–<2.5 mg/dl 1
>2.5 mg/dl 2
DDS, deceased donor score; HCV, hepatitis C virus.
Kidney International Reports (2017) 2, 53–59HCV-AB result has been obtained.15 When NAT for
HCV RNA was used for the extended virological
screening, 20 of 28 (71%) anti-HCV-reactive donors
were negative for HCV-RNA and were predicted to
transmit HCV infection with a very low probability.1,29
Thus, 21 renal allografts of these 20 donors were
transplanted to HCV-negative recipients. The expected
result from transplanting an anti-HCV-reactive but
HCV-RNA-negative organ to a recipient without HCV
infection was the lack of de novo HCV infection as has
been described before by Aeder et al.30 Indeed, in our
series of HCV-negative recipients, no de novo HCV
infection occurred. Interestingly, the quality of the 21
allografts was judged as category A or B based on the
deceased donor score. Moreover, 5-year graft survival
was excellent with 75%. Previous studies showed
increased mortality of patients receiving renal allo-
grafts from donors with positive anti-HCV antibodies
as compared with recipients of HCV-negative or-
gans.31–34 However, in these studies, donors could not
be stratiﬁed according to viral load. Nevertheless, re-
cipients of HCV-positive organs still showed an
advantage in survival compared with matched patients
remaining on the waiting list.31–34 Thus, excluding all
HCV-reactive donors without further evaluation of
viremia may lead to loss of signiﬁcant numbers of renal
allografts suitable for HCV-negative recipients.
Extended virological testingwas performed inmost of
the cases at the recipient center and did not signiﬁcantly
inﬂuence the median cold ischemia time. Modern point-
of-care systems for detection of HCV-RNA have a low
turnaround time of the test results and are no limiting
factor in the transplantation procedure; usually modern
NAT assays take no longer than 6 hours. However, these
assays need a certain expertise and should be performed
by trained specialists. Thus, specialized personnel needs
to be available on request to perform these assays.
Therefore, it is possible to perform sophisticated, addi-
tional testing to obtain information on infectivity of
HCV-reactive donors within the time frame of organ
procurement and transplantation.
Importantly, ODS showing reactivity for HCV-
AB screening must be interpreted as current HCV
infection if there is no further screening for viremia
available. Transplantation of these organs is only safe57
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ation.1,27,35–37 The KDIGO guidelines for hepatitis in
chronic kidney disease state that “.kidney donors are
best screened for HCV infection using NAT, which is the
optimal way to distinguish between donors who may or
may not be potentially infectious..”9,14 Although the
KDIGO clinical practice guidelines for the prevention,
diagnosis, evaluation, and treatment of HCV infection in
chronic kidney disease and the resulting European Renal
Best Practice statement suggest “.that transplantation
of kidneys from donors infected with HCV should be
restricted to recipients with positive HCV RNA
results.,” it is also acknowledged in the very same
document that “.not all anti-HCV-positive donors are
viremic, so discarding kidneys fromEIA-positive donors
will result in the loss of kidney that could otherwise be
used..”9 The grade of recommendation is weak because
it results from a consensus-based recommendation. The
statement of the American Society of Transplant sur-
geons is even more reserved concerning HCV-positive
organ donors.38 The National Kidney Foundation sug-
gested in their commentary to the KDIGO guideline that
a registry should track clinical outcomes ofHCV-positive
recipients transplanted with kidneys of HCV-infected
donors.39 Currently, there is no registry for this entity
of patients and long-term data are rare. Therefore, ac-
curate and long-term follow-up of patients receiving
kidneys fromHCV-reactive donors—as performed at our
center—is needed urgently. We have to emphasize that
our series started long before the current guidelineswere
published. Recently, novel antiviral drugs have become
available that induce a sustained virological response—
that is, absence of viremia—in patients with chronic
HCV infection.40 In future, these drugs may allow pre-
vention or treatment of HCV infection in recipients
receiving renal allografts of viremic donors. Therefore,
viremic donors with chronic HCV infection might be a
potential source of donors in the future.41,42 In addition,
the number of HCV-positive, nonviremic donors may
increase as a result of the new therapeutic strategies.
Thus, the application of NAT for organ donor testing
will increase andmight become routine. The risk of HCV
transmission is—if this strategy is applied more
widely—low but not zero. Accordingly, a recent case
series reported transmission of HCV from 3 organ donors
with negative NAT.43 However, all donors could be
classiﬁed as “high-risk donors” retrospectively. This
case series demonstrates that careful stratiﬁcation of
donors according to risk behavior forHCV infection such
as nonmedical drug injection will become more impor-
tant.43,44 Our study has some limitations. It is a retro-
spective, noncontrolled study, and as a single center
trial, it carries a bias risk. On the other hand, our study is
one of the largest case series on this topic. The presented58data indicate clearly that HCV-AB-positive organs can be
transplanted if extended virological testing is imple-
mented. Even if this approach improves the organ
shortage only slightly, it is an opportunity.
In conclusion, these data conﬁrm that trans-
plantation of renal allografts from nonviremic HCV-AB-
reactive donors to HCV-negative recipients is safe.
HCV-AB-reactive organs should not be denied for
transplantation in general; as has been demonstrated in
our series, organ quality and graft survival are not
inferior. Thus, transplantation of HCV-AB-reactive
renal allografts to HCV-negative recipients should be
considered after extended virological testing, and
comprehensive informed consent needs to be obtained
from the recipient.
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